Cargando…

Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection

Atazanavir/cobicistat (ATV/c) and darunavir/cobicistat (DRV/c) are newly approved once daily fixed-dose protease inhibitor combinations for the treatment of HIV-1 infection. Studies in healthy volunteers have established bioequivalence between cobicistat and ritonavir as pharmacoenhancers of both at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crutchley, Rustin D, Guduru, Rakesh C, Cheng, Amy M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790521/ https://www.ncbi.nlm.nih.gov/pubmed/27022304 http://dx.doi.org/10.2147/HIV.S99063

Ejemplares similares

Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS
por: Navarro, Jordi, et al.
Publicado: (2016)

Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir: Various toxicities and off-label use: 9 case reports
Publicado: (2020)

Rationale and clinical utility of the darunavir–cobicistat combination in the treatment of HIV/AIDS
por: Putcharoen, Opass, et al.
Publicado: (2015)

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
por: Moore, Katy, et al.
Publicado: (2022)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19
por: Chen, Jun, et al.
Publicado: (2020)

Data on the stability of darunavir/cobicistat suspension after tablet manipulation
por: Zanon, D., et al.
Publicado: (2020)

Reply to: “Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19”
por: Nicolini, Laura Ambra, et al.
Publicado: (2020)

Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations
por: Gutierrez‐Valencia, Alicia, et al.
Publicado: (2018)

Effect of monotherapy with darunavir/cobicistat on viral load and semen quality of HIV-1 patients
por: López-Ruz, Miguel A., et al.
Publicado: (2018)

Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice
por: Ranzenigo, Martina, et al.
Publicado: (2022)

Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
por: Solana-Altabella, Antonio, et al.
Publicado: (2022)

Exploration of Reduced Doses and Short-Cycle Therapy for Darunavir/Cobicistat in Patients with HIV Using Population Pharmacokinetic Modeling and Simulations
por: Stillemans, Gabriel, et al.
Publicado: (2020)

Switching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice [Corrigendum]
Publicado: (2022)

Ceftriaxone/cobicistat/darunavir/hydroxychloroquine: Off-label use and lack of efficacy: case report
Publicado: (2022)

Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era
por: Squillace, Nicola, et al.
Publicado: (2018)

Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide
por: Chow, Wing, et al.
Publicado: (2020)

Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression
por: Antinori, Andrea, et al.
Publicado: (2020)

Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection
por: Kim, Eun Jin, et al.
Publicado: (2020)

Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study
por: Elmekaty, Eman Zeyad I., et al.
Publicado: (2022)

Correction to: Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression
por: Antinori, Andrea, et al.
Publicado: (2020)

Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study
por: Di Castelnuovo, Augusto, et al.
Publicado: (2021)

A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults
por: Huhn, Gregory D., et al.
Publicado: (2017)

A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients
por: Eron, Joseph J., et al.
Publicado: (2018)

Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial
por: Tashima, Karen, et al.
Publicado: (2014)

HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study
por: Harris, Marianne, et al.
Publicado: (2017)

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study
por: Huhn, Gregory D., et al.
Publicado: (2019)

Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor–Based Regimen: The “STORE” Study
por: Gori, Andrea, et al.
Publicado: (2020)

A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes
por: Santos, José R, et al.
Publicado: (2023)

ODP596 Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir
por: Chen, Ying, et al.
Publicado: (2022)

Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)
por: Taramasso, Lucia, et al.
Publicado: (2019)

Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial(§)
por: Gallant, Joel, et al.
Publicado: (2017)

Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults
por: Tashima, Karen, et al.
Publicado: (2014)

Combination Therapy with Tenofovir Disoproxil Fumarate/Emtricitabine/Elvitegravir/Cobicistat Plus Darunavir Once Daily in Antiretroviral-Naive and Treatment-Experienced Patients: A Retrospective Review
por: Naccarato, Mark J., et al.
Publicado: (2018)

Cobicistat: a Novel Pharmacoenhancer for Co-Formulation with HIV Protease and Integrase Inhibitors
por: Nathan, Bavithra, et al.
Publicado: (2013)

Effectiveness, Safety, and Tolerability of a Switch to Dual Therapy with Dolutegravir Plus Cobicistat-Boosted Darunavir in Treatment-Experienced Patients with Human Immunodeficiency Virus
por: Lee, Sang-Ah, et al.
Publicado: (2018)

SAT331 A Case Of Iatrogenic Cushing’s Syndrome Due To The Concomitant Use Of Cobicistat With An Inhaled Glucocorticoid Followed By Adrenal Insufficiency Upon Discontinuation Of Cobicistat
por: Noor, Laila, et al.
Publicado: (2023)

The effect of ivermectin alone and in combination with cobicistat or elacridar in experimental Schistosoma mansoni infection in mice
por: Vicente, Belén, et al.
Publicado: (2021)

Rifabutin-Cobicistat Drug Interaction Resulting in Severe Bilateral Panuveitis
por: Toomey, Christopher B., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4q246ce469rk0cps3lkqppcpdt